新生儿口服苯巴比妥预防高胆红素血症的临床观察  

Prevention of neonate’s hyperbilirubiemia by orally taking peroral phenobarbital sodium

作　　者：赵新霞[1] 成晓霞[1] 段晓燕[1] 李凤英[1] 

机构地区：[1]湖北省妇幼保健院,湖北武汉430070

出　　处：《南方护理学报》2001年第2期3-4,共2页Nanfang Journal of Nursing

摘　　要：目的　探讨口服苯巴比妥对预防新生儿高胆红素血症的作用。方法　选择 80例母婴同室的新生儿 ,随机分成服药组和对照组各 40例 ,于生后 1天在服药组开始口服苯巴比妥 5mg/kg ,每日 2次 ,共 3天。对照组不服用药物。结果　服药组新生儿高胆红素血症发病率和胆红素整体水平明显低于对照组 (P <0 .0 1)。结论　口服苯巴比妥预防新生儿高胆红素血症疗效明显。Objective To investigate the effects of oral administration of peroral Phenobarbital sodium in prevention of neonate’s hyperbilirubiemia.Methods 80 cases of noeonates together with their mothers in the same ward were evenly divided into two groups:the drug-taking group and control group,each 40 cases.In the experimental group,the neonates were given oral administration of 5 mg/kg peroral Phenobarbital sodium twice a day for 3 days.In the latter,the cases took no durg.Results The morbidity of neonate’s hyperbilirubiemia and the level of total bilirubin in the experimental group were signifcantly lower that in contraol group.Conclusion Oral administration of peroral phenobarbital sodium is effective in the prevention of neonate hyperbilirubiemia.

关 键 词：新生儿 高胆红素血症 苯巴比妥 预防 

分 类 号：R722.170.1[医药卫生—儿科]